A triple dose of optimism: an initial foray into triplet therapy in metastatic renal cell carcinoma

Affiliations

¹ Division of Hematology and Oncology, Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center, Nashville, TN, USA.
² Division of Hematology and Oncology, Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center, Nashville, TN, USA. brian.rini@vumc.org.

Kathryn E Beckermann et al. Nat Rev Clin Oncol. 2023 Sep.

. 2023 Sep;20(9):581-582.

doi: 10.1038/s41571-023-00795-6.

¹ Division of Hematology and Oncology, Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center, Nashville, TN, USA.
² Division of Hematology and Oncology, Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center, Nashville, TN, USA. brian.rini@vumc.org.

No abstract available

References

1. Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018). - DOI - PubMed - PMC
1. Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116–1127 (2019). - DOI - PubMed
1. Motzer, R. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N. Engl. J. Med. 384, 1289–1300 (2021). - DOI - PubMed
1. Williams, S. D., Loehrer, P. J., Nichols, C. R. & Einhorn, L. N. Chemotherapy of male and female germ cell tumors. Semin. Oncol. 19(Suppl 5), 19–23 (1992). discussion 23–24. - PubMed
1. Choueiri, T. K. et al. Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma. N. Engl. J. Med. 388, 1767–1778 (2023). - DOI - PubMed